
Shares of drug developer Ventyx Biosciences VTYX.O surge 67% to $16.79 premarket
Eli Lilly LLY.N in advanced talks to buy VTYX for more than $1 billion, WSJ reported on Tuesday
Potential agreement will add drugs for inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, to Lilly's pipeline
Stock soared roughly 220% to $25 immediately following the report on Tuesday, before Nasdaq temporarily halted trading on the stock
VTYX closed Tuesday up 28.5%, with a market cap of $717.15 million - data compiled by LSEG
VTYX stock more than quadrupled in 2025